Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$325.40 USD

325.40
996,860

+3.49 (1.08%)

Updated Nov 8, 2024 03:42 PM ET

After-Market: $324.67 -0.73 (-0.22%) 4:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Amgen (AMGN) Gains But Lags Market: What You Should Know

Amgen (AMGN) closed at $228.93 in the latest trading session, marking a +0.11% move from the prior day.

AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss

AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares up.

Is a Beat Likely for Amgen (AMGN) This Earnings Season?

Volume growth from Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.

Will Merck (MRK) Succeed in Beating Q4 Earnings Expectations?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q4 earnings.

Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store?

Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.

Is a Beat Likely for Biogen (BIIB) This Earnings Season?

Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports fourth-quarter results.

Will Eylea, Dupixent Aid Regeneron's (REGN) Q4 Earnings?

Regeneron's (REGN) fourth-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.

Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.

Can Value Investors Select Amgen (AMGN) Stock Now?

Is Amgen (AMGN) a great pick from the value investor's perspective right now? Read on to know more.

Why Amgen (AMGN) Might Surprise This Earnings Season

Amgen (AMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sheraz Mian headshot

Top Research Reports for Meta Platforms, UnitedHealth & salesforce

Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (FB), UnitedHealth Group Incorporated (UNH), and salesforce.com, inc. (CRM).

Amgen (AMGN) Gains As Market Dips: What You Should Know

In the latest trading session, Amgen (AMGN) closed at $224, marking a +0.66% move from the previous day.

Amgen (AMGN) to Report Q4 Results: Wall Street Expects Earnings Growth

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) Stock Moves -0.52%: What You Should Know

Amgen (AMGN) closed the most recent trading day at $227.72, moving -0.52% from the previous trading session.

Amgen's (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer

Amgen's (AMGN) KRAS inhibitor, Lumakras, gets approval in Japan for the treatment of KRAS G12C-mutated positive advanced/recurrent non-small-cell lung cancer.

J&J (JNJ) to Set the Stage for Pharma Sector Q4 Earnings

J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the fourth quarter.

Amgen (AMGN) Stock Moves -1.04%: What You Should Know

Amgen (AMGN) closed at $228.90 in the latest trading session, marking a -1.04% move from the prior day.

CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors

The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

Amgen (AMGN) closed at $235.36 in the latest trading session, marking a +1.95% move from the prior day.

BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study

BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.

Stock Market News for Jan 13, 2022

U.S. stocks closed slightly higher on Wednesday after data showed that inflation hit a four-decade high but came in largely in line with economists' expectations.

Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates

Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.

Why the Earnings Surprise Streak Could Continue for Amgen (AMGN)

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Amgen (AMGN) Gains As Market Dips: What You Should Know

Amgen (AMGN) closed at $230.37 in the latest trading session, marking a +1.36% move from the prior day.